SCHEMBL22979036

SCHEMBL22979036

NNC(=O)c1ccc(F)cc1OC(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.45
EPHX2 P34913 1/20 0.44
KCNK3 O14649 4/20 0.43
KCNK9 Q9NPC2 4/20 0.43
PYGL P06737 1/20 0.43
F2R P25116 1/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 1/20 0.40
GFER P55789 1/20 0.40
MAPT P10636 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MITF O75030 1/20 0.38
NCOA1 Q15788 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
AVPR2 P30518 1/20 0.38
GPR27 Q9NS67 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29646420 0.88 SCN8A (0.48) CTSDEPHX2KCNK3KCNK9PYGL
SCHEMBL22980163 0.88 SCN8A (0.48) CTSDEPHX2KCNK3KCNK9PYGL
SCHEMBL22979567 0.83 MAOA (0.44) CTSDEPHX2KCNK3KCNK9F2R
SCHEMBL22979526 0.83 KDM4E (0.57) CTSDKMT2AKDM4EGAAALDH1A1
SCHEMBL29646406 0.82 CTSD (0.62) CTSDKCNK3KCNK9F2RKMT2A
SCHEMBL376957 0.82 CTSD (0.62) CTSDKCNK3KCNK9F2RKMT2A
Hydrochloric Acid SCHEMBL5800475 0.81 CTSD (0.60) CTSDKCNK3KCNK9F2RKMT2A
SCHEMBL4338344 0.81 CTSD (0.65) CTSDGAAALDH1A1MAPT
SCHEMBL22978965 0.81 TP53 (0.50) CTSDKCNK3KCNK9KMT2AKDM4E
SCHEMBL17339467 0.80 PYGL (0.46) EPHX2KCNK3KCNK9PYGLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
CN-114466850-A [1,2,4] triazolo [1,5-C ] quinazolin-5-amines 拜耳股份有限公司 2022-05-10 CN disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 CTSD 3441/4885EPHX2 635/4885KCNK3 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.